Press Release

Our company's new compound drug NDF01 for the treatment of HIV infection has been approved by the Ministry of Health and Welfare

Our company's new compound drug NDF01 for the treatment of HIV infection was approved and obtained the drug license, and we received the approval letter on January 8, 2025.

Based on the announcement from the Ministry of Health and Welfare (Health Food No. 1120726627).

This product is a new compound new drug:

A. Certification number: Ministry of Health Pharmaceutical Factory No. 061903.

B. Chinese and English product name: AidzPir Film Coated Tablets.

C. Indications: For patients with type 1 virus who are over 12 years old and weigh at least 35 kg and have not previously received antiretroviral therapy and are treated with a combination of efavirenz, lamivudine and tenofovir. Immunodeficiency virus (HIV-1) infected patients who do not have a mutation known to confer resistance to the fifth component of this product.

The sterile vial line-2 of UBIP's expanded factory passed the GMP inspection of the Ministry of Health and Welfare.

Employee Travel Leave Notice

2024/05/15

Explanation of UBI Pharma's cessation of stock trading on the Taipei Exchange and the current operational status of the company

2024/05/07

UBI Pharma announces its participation in the '2024 TALENT, in Taiwan' alliance for sustainable talent development in Taiwan."

2024/05/03

UBI Pharma's explanation for the termination of stock trading on the Taipei Exchange

2024/05/02

UBI Pharma passes GMP inspection by the UK MHRA.

UBI Pharma applies to the Taiwan Food and Drug Administration (TFDA) for drug inspection registration of the biosimilar drug erythropoietin UB-851.

UBI Pharma passes GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

2023/12/05

UBI Pharma obtains a US patent certificate for the "Single-Chain Immunoglobulin Fusion Protein Technology Platform."

2023/10/31

UBI Pharma applies to the TFDA for drug inspection registration of the new compound drug NDF01 for the treatment of HIV infection.

2023/09/14

UBI Pharma signs an investment and exclusive licensing sales agreement with Ory Biotech Co., Ltd. for the bio-similar drug UB-851.

UBI Pharma's Hsinchu plant receives formal Establishment Inspection Report (EIR) approval from the United States Food and Drug Administration (FDA).

UBI Pharma's proprietary product, Voriconazole Injection, has received approval for Abbreviated New Drug Application (ANDA) from the United States.

2023/03/20

UBI Pharma Inc. responds to community greening and carbon reduction tree planting activities

UBI Pharma Inc. responds to community greening and carbon reduction and participates in the Hsinchu County Government’s 2023 tree planting event to create sustainable green resources.